Thanks to the work of Fred Hutch/University of Washington clinical researchers, a big discovery may soon make a “big, big impact” on patients dealing with two intractable cancers: tubo-ovarian and tri...

When Margie Wilson was diagnosed with endometrial cancer in 2016 after she experienced unexplained bleeding, she knew nothing about cancer. She didn’t even know what an oncologist does. A decade late...

Petros Grivas, MD, PhD, FASCO sits down Heather Cheng, MD, PhD, director of the genetics program at Fred Hutch Cancer Center, to discuss how germline and tumor testing inform cancer care

A study published in the journal Nature of more than 60,000 RSV sequences found resistance-associated variants to two monoclonal antibody treatments are rare and provides a roadmap to help guide the d...

In this fifth episode of our Survivorship series on Bench to Bedside and Beyond, Fred Hutch News writer Bonnie Rochman talks to James DeLong, who has lived with prostate cancer for more than two decad...

Combinatorial pairing of independently recombined T cell receptor (TCR) α- and β-chains is central to diversifying the TCR repertoire. Although sequence motifs in one chain correlate with epitope reco...

Fred Hutch researchers show in recent study how aggressive prostate cancer shapeshifts from a form that is treatable with drugs to a more lethal form that is much less treatable. The study also descri...

Help Fred Hutch Cancer Center advance innovative research. Donate today!

U.S. health officials have approved a groundbreaking pancreatic cancer drug that offers a new approach to treating the deadly form of cancer.

Fred Hutch researchers show in recent study how aggressive prostate cancer shapeshifts from a form that is treatable with drugs to a more lethal form that is much less treatable. The study also descri...

Leah Speser recently created a nearly $300,000 endowment at Fred Hutch to support postdoctoral researchers at Fred Hutch. This idea to support the people who “form the next generation of science” was ...